Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2Q Pharma Results Preview: Novartis And J&J Lead The Pack

Executive Summary

Scrip offers some top topics to monitor as second-quarter biopharmaceutical sales and earnings start to be unveiled. First out of the blocks will be Johnson & Johnson and Novartis AG. Recent and coming launches, pricing strategies, M&A and the biosimilar landscape are key themes to watch out for as the duo and other players update at their half-year points.

Advertisement

Related Content

Commercial Capsules: Soriot, IPOs, Deals And Hemophilia Data
J&J's First-In-Class Tremfya Poised To Join A Crowded Psoriasis Market
Novartis' CAR-T Poised For The Market After Unanimous FDA Adcomm Review
Novartis' Brolucizumab Shows Dose Advantage Over Eylea In nAMD Trials
Entresto Facing Pressure From Diabetes Drugs
Darzalex Setback In NHL Raises Stakes For First-Line Myeloma Approval

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099127

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel